Showing results (201-210 of 1,246) with videos related to
Sort By:
Pageof 125
Antimicrobial Agents and Chemotherapy|July 1, 1995
Susceptibilities of several drug-resistant herpes simplex virus type 1 strains to alternative antiviral compoundsG Andrei, R Snoeck, E De ClercqJournal of Medical Virology|May 1, 1987
Serum and urine concentrations of oral bromovinyldeoxyuridine in humans as monitored by a bioassay system based on varicella-zoster virus focus inhibitionM Baba, S Shigeta, E De ClercqAntiviral Research|June 1, 2004
In vitro selection of drug-resistant varicella-zoster virus (VZV) mutants (OKA strain): differences between acyclovir and penciclovir?G Andrei, E De Clercq, R SnoeckJournal of Steroid Biochemistry|September 1, 1988
Stimulatory effects of antiviral adenosine analogs on steroidogenesis in Leydig cellsG Verhoeven, J Cailleau, E De ClercqArzneimittel-Forschung|March 1, 1989
[Penetration and action of edoxudine in vitro and in vivo]R Kaul, B Hempel, E De ClercqMolecular Pharmacology|November 6, 1998
Enhanced 9-(2-phosphonylmethoxyethyl)adenine secretion by a specific, indomethacin-sensitive efflux pump in a mutant 9-(2-phosphonylmethoxyethyl)adenine-resistant human erythroleukemia K562 cell lineS Hatse, E De Clercq, J BalzariniAntiviral Research|January 1, 1987
Phosphorylation of nucleoside analogs by equine herpesvirus type 1 pyrimidine deoxyribonucleoside kinaseS Kit, H Ichimura, E De ClercqThe Journal of Biological Chemistry|April 15, 1989
Differential patterns of intracellular metabolism of 2',3'-didehydro-2',3'-dideoxythymidine and 3'-azido-2',3'-dideoxythymidine, two potent anti-human immunodeficiency virus compoundsJ Balzarini, P Herdewijn, E De ClercqCurrent Drug Targets. Infectious Disorders|November 29, 2002
HIV-1 integration as a target for antiretroviral therapy: a reviewW Pluymers, E De Clercq, Z DebyserDrugs|April 3, 1999
Current pharmacological approaches to the therapy of varicella zoster virus infections: a guide to treatmentR Snoeck, G Andrei, E De ClercqPageof 125